Vaccine enthusiasm backs off
Equities moved lower in the latter half of the week.
According to Chris Beauchamp, Chief Market Analyst at IG, this was due to “the vaccine bounce” fading across markets.
eToro analyst Adam Vettese noticed the same thing.
“European markets were in the red, coming off their highs as infection rates continue to rise and the realisation that a vaccine is not an overnight fix dawns on investors,” Vettese said
“Despite breakthrough news from Pfizer’s vaccine trial this week, there is yet to be approval and the logistics of transporting a vaccine that must be kept at sub zero temperatures is beset with issues.”
Beauchamp noted the slow down “As enthusiasm about a vaccine begins to fade the FTSE 100 has lost ground, with a slowdown in the excited buying of hard-hit value names in sectors like travel, airlines, banks and others.
“In Europe it is a similar story, but overall, it feels like a pause rather than the beginning of a reversal.
As for the general market performance, Beauchamp noted the mixed performances.
“UK GDP data showed a strong rebound for Q3, although slightly below estimates, and any positive feelings created by the report were muted thanks to the evident slowdown in September from the euphoric performance in July and August.
“It was another mixed bag of corporate data in the UK, as B&M said that it would issue a special dividend following strong performance, while those outside of the discount bin-end of the market continue to struggle.
“WHSmith’s winning bet on international travel, such a sure thing until this year, has come unstuck, with sales in this division dropping more sharply than the old-fashioned high-street arm.
“US futures are also weaker, as the ‘rotation’ of the last few days gives way to a more ‘normal’ pattern as investors flow back towards oversold tech stocks.
“Political developments, or lack thereof, continue to have little impact, with the lack of any White House pronouncements helping to calm market nerves about the US political outlook.”
- Dow: -0.08%
- S&P 500: -1.00%
- NASDAQ: -0.65%
- FTSE 100: -0.68%
- DAX: -1.24%
- CAC40: -1.52%
- Asia Dow: -0.19%
- Nikkei 225: +0.68%
- Hang Seng: -0.22%
- ASX XAO (All Ordinaries): -0.48%
- ASX 200 (XJO): -0.49%
- AUD: 0.72
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.